Ontology highlight
ABSTRACT: Purpose
The adenosine A2A receptor has emerged as a therapeutic target for multiple diseases, and thus the non-invasive imaging of the expression or occupancy of the A2A receptor has potential to contribute to diagnosis and drug development. We aimed at the development of a metabolically stable A2A receptor radiotracer and report herein the preclinical evaluation of [18F]FLUDA, a deuterated isotopologue of [18F]FESCH.Methods
[18F]FLUDA was synthesized by a two-step one-pot approach and evaluated in vitro by autoradiographic studies as well as in vivo by metabolism and dynamic PET/MRI studies in mice and piglets under baseline and blocking conditions. A single-dose toxicity study was performed in rats.Results
[18F]FLUDA was obtained with a radiochemical yield of 19% and molar activities of 72-180 GBq/μmol. Autoradiography proved A2A receptor-specific accumulation of [18F]FLUDA in the striatum of a mouse and pig brain. In vivo evaluation in mice revealed improved stability of [18F]FLUDA compared to that of [18F]FESCH, resulting in the absence of brain-penetrant radiometabolites. Furthermore, the radiometabolites detected in piglets are expected to have a low tendency for brain penetration. PET/MRI studies confirmed high specific binding of [18F]FLUDA towards striatal A2A receptor with a maximum specific-to-non-specific binding ratio in mice of 8.3. The toxicity study revealed no adverse effects of FLUDA up to 30 μg/kg, ~ 4000-fold the dose applied in human PET studies using [18F]FLUDA.Conclusions
The new radiotracer [18F]FLUDA is suitable to detect the availability of the A2A receptor in the brain with high target specificity. It is regarded ready for human application.
SUBMITTER: Lai TH
PROVIDER: S-EPMC8263428 | biostudies-literature | 2021 Aug
REPOSITORIES: biostudies-literature
European journal of nuclear medicine and molecular imaging 20210202 9
<h4>Purpose</h4>The adenosine A<sub>2A</sub> receptor has emerged as a therapeutic target for multiple diseases, and thus the non-invasive imaging of the expression or occupancy of the A<sub>2A</sub> receptor has potential to contribute to diagnosis and drug development. We aimed at the development of a metabolically stable A<sub>2A</sub> receptor radiotracer and report herein the preclinical evaluation of [<sup>18</sup>F]FLUDA, a deuterated isotopologue of [<sup>18</sup>F]FESCH.<h4>Methods</h4> ...[more]